title: New allergies after cord blood transplantation.
abstract: OBJECTIVE
  Umbilical cord blood transplantation (CBT) is an effective treatment for benign and malignant diseases. Late effects of CBT are not well described in the literature. In the present study, we present our experience of new-onset allergies in long-term survivors after CBT.
  
  
  METHODS
  After an initial patient had a severe peanut allergic reaction after CBT, all CBT patients were prospectively followed for new allergy development. Fifty patients received CBT between March 2006 and June 2011.
  
  
  RESULTS
  The median follow-up after CBT was 447 days (range, 12-2022). At the time of analysis, 30 patients were alive, with 3-year survival of 55.5%; median follow-up of surviving patients was 910 days (range, 68-2022). The allergic syndrome developed in five patients, with the cumulative incidence of new allergies at 2 years of 18.4% (95% confidence interval, 10.8-26). The median time to onset of new allergy after transplantation was 298 days (range, 250-809).
  
  
  CONCLUSIONS
  Allergy development has been linked to a delayed maturation of the immune system in several studies. We present the first case series of patients who had new allergies after CBT. Further study of this novel complication as well as counseling of patients after CBT would be important.
authors.affiliation: Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
authors.forename: Leigh Ann
authors.initials: LA
authors.lastname: Vaughan
authors.forename: Mary
authors.initials: M
authors.lastname: Vu
authors.forename: Salyka
authors.initials: S
authors.lastname: Sengsayadeth
authors.forename: Catherine
authors.initials: C
authors.lastname: Lucid
authors.forename: Carey
authors.initials: C
authors.lastname: Clifton
authors.forename: Karen
authors.initials: K
authors.lastname: McCarty
authors.forename: David
authors.initials: D
authors.lastname: Hagaman
authors.forename: Jennifer
authors.initials: J
authors.lastname: Domm
authors.forename: Adetola
authors.initials: A
authors.lastname: Kassim
authors.forename: Wichai
authors.initials: W
authors.lastname: Chinratanalab
authors.forename: Stacey
authors.initials: S
authors.lastname: Goodman
authors.forename: John
authors.initials: J
authors.lastname: Greer
authors.forename: Haydar
authors.initials: H
authors.lastname: Frangoul
authors.forename: Brian G
authors.initials: BG
authors.lastname: Engelhardt
authors.forename: Madan
authors.initials: M
authors.lastname: Jagasia
authors.forename: Bipin N
authors.initials: BN
authors.lastname: Savani
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy*; D006801:Humans; D006967:Hypersensitivity / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality; D015994:Incidence; D007223:Infant; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology* / Q000401:mortality; D011446:Prospective Studies; D016019:Survival Analysis; D013997:Time Factors; D055815:Young Adult
keywords: allergies; cord blood transplantation; hematological malignancies